Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
EnteroBiotix secures £27M in a Series B funding round to advance donor-derived gut bacteria for IBS treatment. The FDA-approved treatment aims to replace fecal microbiota transplants.
PRIVATEAug 20, 2026•about 4 hours ago
Amount Raised
£27 Million
Round Type
Series B
GlasgowBiotechnology
Description
EnteroBiotix, based in Scotland, has successfully raised £27 million in a Series B funding round. This funding will be used to develop pharmaceutical-grade capsules of donor-derived gut bacteria for the treatment of Irritable Bowel Syndrome (IBS). Their leading candidate is currently in a Phase IIa trial. This innovative approach could revolutionize treatment options for patients with IBS.
Company Information
Company
EnteroBiotix
Location
Phoenix House
Glasgow, Scotland, United Kingdom
About
EnteroBiotix is a leading microbiome therapeutics platform company that is focussed on transforming the standard of care for patients battling debilitating diseases and infections linked to disruptions to structure and function of the gut microbiome.
Don't miss EnteroBiotix's next move
Get an email the moment EnteroBiotix raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
Suggested for you
1 contact
Predictive Intelligence
Strategic
ML-powered predictions for EnteroBiotix's next move
GlasgowBiotechnology